二肽基肽酶-Ⅳ抑制剂的研究进展

被引：11

作者：

董琳琳 ^{[1
]}

昌盛 ^{[2
]}

机构：

[1] 延边大学药学院

[2] 吉林医药学院药学院

来源：

吉林医药学院学报 | 2017年 / 38卷 / 02期

关键词：

糖尿病; 二肽基肽酶-Ⅳ抑制剂;

D O I：

10.13845/j.cnki.issn1673-2995.2017.02.021

中图分类号：

R977.15 [];

学科分类号：

摘要：

糖尿病是严重危害人类健康的疾病之一患病人数逐年激增。二肽基肽酶-Ⅳ抑制剂通过抑制体内二肽基肽酶-Ⅳ的部分活性,在抑制肠促激素分解的同时增强胰岛β细胞的再生能力,进而可以有效防止或延缓糖尿病的发生,改善糖耐量异常以及增加胰岛素的敏感性。二肽基肽酶作为糖尿病治的一个新靶点,受到了广泛的关注。本文对已经上市的二肽基肽酶-Ⅳ抑制剂的作用机制、临床疗效、不良反应以及治疗2型糖尿病的优势进行逐一综述。

引用

页码：130 / 134

页数：5

共 20 条

[1]

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus [J].

Addy, Carol ;

Tatosian, Daniel ;

Glasgow, Xiaoli S. ;

Gendrano, Isaias N., III ;

Kauh, Eunkyung ;

Martucci, Ashley ;

Johnson-Levonas, Amy O. ;

Selverian, Diana ;

Matthews, Catherine Z. ;

Gutierrez, Marie ;

Wagner, John A. ;

Stoch, S. Aubrey .

CLINICAL THERAPEUTICS, 2016, 38 (03) :516-530

[2]

A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats [J].

Kimura, Shinichiro ;

Inoguchi, Toyoshi ;

Yamasaki, Toshihide ;

Yamato, Mayumi ;

Ide, Makoto ;

Sonoda, Noriyuki ;

Yamada, Kenichi ;

Takayanagi, Ryoichi .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (03) :138-145

[3]

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial [J].

Zannad, Faiez ;

Cannon, Christopher P. ;

Cushman, William C. ;

Bakris, George L. ;

Menon, Venu ;

Perez, Alfonso T. ;

Fleck, Penny R. ;

Mehta, Cyrus R. ;

Kupfer, Stuart ;

Wilson, Craig ;

Lam, Hung ;

White, William B. ;

Aiub, Jorge ;

Albisu, Juan ;

Alvarez, Carlos ;

Astesiano, Alfredo ;

Barcudi, Raul ;

Bendersky, Mario ;

Bono, Julio ;

Bustos, Betina ;

Cartasegna, Luis ;

Caruso, Orlando ;

Casabe, Horacio ;

Castro, Remo ;

Colombo, Hugo ;

Cuneo, Carlos ;

Cura, Fernando ;

De Loredo, Luis ;

Dran, Ricardo ;

Fernandez, Horacio ;

Garcia Pinna, Jorge ;

Hrabar, Adrian ;

Klyver de Saleme, Maria ;

Luquez, Hugo ;

Mackinnon, Ignacio ;

Maffei, Laura ;

Majul, Claudio ;

Mallagray, Marcelo ;

Marino, Javier ;

Martinez, Diego ;

Martingano, Roberto ;

Nul, Daniel ;

Leonor Parody, Maria ;

Petrucci, Jacqueline ;

Pieroni, Mario ;

Piskorz, Daniel ;

Prado, Aldo ;

Ramos, Hugo ;

Resk, Jorge ;

Rodriguez, Marcelo .

LANCET, 2015, 385 (9982) :2067-2076

[4]

Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin [J].

Wang, Man-man ;

Lin, Shuo ;

Chen, Yan-ming ;

Shu, Jiong ;

Lu, Hong-yun ;

Zhang, Yong-jun ;

Xie, Ru-ying ;

Zeng, Long-yi ;

Mu, Pan-wei .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (03) :E67-E70

[5]

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study [J].

Inagaki, Nobuya ;

Onouchi, Hitoshi ;

Maezawa, Hideaki ;

Kuroda, Shingo ;

Kaku, Kohei .

LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (03) :191-197

[6]

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV(DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective [J].

Kushwaha, R. N. ;

Haq, W. ;

Katti, S. B. .

CURRENT MEDICINAL CHEMISTRY, 2014, 21 (35) :4013-4045

[7]

Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials [J].

Gao, W. ;

Dong, J. ;

Liu, J. ;

Li, Y. ;

Liu, F. ;

Yang, L. ;

Zhou, X. ;

Liao, L. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :179-185

[8]

Effets cardiovasculaires des inhibiteurs de la DPP-4.[J].B. Vergès.Médecine des maladies métaboliques.2013, 3

[9]

A review of the efficacy and safety of oral antidiabetic drugs [J].

Stein, Stephanie Aleskow ;

Lamos, Elizabeth Mary ;

Davis, Stephen N. .

EXPERT OPINION ON DRUG SAFETY, 2013, 12 (02) :153-175

[10]

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Rhee, E. J. ;

Lee, W. Y. ;

Min, K. W. ;

Shivane, V. K. ;

Sosale, A. R. ;

Jang, H. C. ;

Chung, C. H. ;

Nam-Goong, I. S. ;

Kim, J. A. ;

Kim, S. W. .

DIABETES OBESITY & METABOLISM, 2013, 15 (06) :523-530

← 1 2 →